Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer ; volume:20 ; number:1 ; day:4 ; month:9 ; year:2018 ; pages:1-13 ; date:12.2018
Breast cancer research ; 20, Heft 1 (4.9.2018), 1-13, 12.2018
- Urheber
-
Buus, Richard
- Beteiligte Personen und Organisationen
-
Yeo, Belinda
Brentnall, Adam R.
Klintman, Marie
Cheang, Maggie Chon U.
Khabra, Komel
Sestak, Ivana
Gao, Qiong
Cuzick, Jack
Dowsett, Mitch
SpringerLink (Online service)
- DOI
-
10.1186/s13058-018-1040-9
- URN
-
urn:nbn:de:101:1-2018102222304125377229
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Buus, Richard
- Yeo, Belinda
- Brentnall, Adam R.
- Klintman, Marie
- Cheang, Maggie Chon U.
- Khabra, Komel
- Sestak, Ivana
- Gao, Qiong
- Cuzick, Jack
- Dowsett, Mitch
- SpringerLink (Online service)
Ähnliche Objekte (12)
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers